Posts Tagged ‘startup’
TheraPPI closes Pre-Seed Financing Round
TheraPPI, a preclinical biotech company operating both in Lyon (France) and Geneva (Switzerland), announced the second closing of its Pre-Seed financing. The amount has not been disclosed. Current shareholders, PULSALYS, FONGIT and new investors with extensive biotech experience have participated to this financing round. TheraPPI is developing protein interaction-modifying drugs to provide patients with better treatments in…
Read MoreMindMaze Therapeutics Narrows Losses and Prepares for Commercial Takeoff in 2026
MindMaze Therapeutics’ 2025 Annual Report tells a story of transition—one where financial discipline begins to align with long-term commercial ambition. The Swiss-based neurotechnology company gears up for a broader market launch in 2026. Mindmaze reported CHF 0.6 million in revenue for 2025, alongside operating expenses of CHF 11.2 million and a net loss of CHF…
Read MoreNourishAI, GenoRobotics and Infera Neuro Get Support from the EPFL Startup Launchpad
Three EPFL-born startups receive key funding to advance breakthrough technologies in health and biology.
Read MoreStudentsPool wins the 10th Patient Quality of Life Challenge
Led by Isa Dupont, a nurse, and Gaspard Chevassus, an engineer, the StudentsPool project is reinventing ad hoc recruitment and connecting students with healthcare institutions to offer assignments serving patients. The project, selected among 5 finalists, received a CHF 25,000 support. The constant turnover of temporary staff undermines the quality of care. Faced with this…
Read MoreBracco, Limula and UNIFR Join Forces to Create Efficient Cancer Cell Therapies
Cell and gene therapies are promising, but remain extremely expensive. The pharmaceutical company Bracco Imaging, a leader in medical imaging, Limula, a company specialising in the automation of cell therapies, and Professor Nicola Vannini of the University of Fribourg are joining forces to make them more accessible. This public-private partnership is receiving CHF 688,000 in…
Read MoreRelief Therapeutics merges with NeuroX to form MindMaze Therapeutics
The new entity, valued at CHF 1.1 billion, is positioned as a leader in neurotechnology. The transaction is expected to close in December 2025. RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, and NeuroX Group SA (NeuroX), a privately held company focused on digital…
Read MoreBioLNP Innovation and OneCell Protein, recipients of the EPFL Startup Launchpad Ignition Grant
Two EPFL-based startups: BioLNP Innovation and OneCell Protein, have become the latest recipients of the EPFL Startup Launchpad Ignition grant. The startups were each awarded a CHF30,000 grant to continue developing their technology. BioLNP Innovation Viruses (including Respiratory Syncytial Virus or Hepatitis B) are a major public health concern. While scientists have developed treatments…
Read MoreEva.J and Bioressant: Pioneering Swiss Neurocosmetics Through Scientific Innovation
In the sophisticated landscape of contemporary skincare, where scientific rigor meets holistic wellness, Swiss company Bioressant and its flagship brand Eva.J Swiss Organic Neurocosmetics stand as exemplars of innovation at the convergence of neuroscience, dermatology, and biotechnology. Founded by Eva Johnston in Lausanne, this pioneering enterprise has established itself as a trailblazer in the emerging…
Read MoreONWARD Medical Receives CE Mark for ARC-EX®
ONWARD Medical, a Vaud-Based neurotechnology company, has achieved a major milestone with the CE Mark certification of its ARC-EX® System. This approval allows the company to launch its breakthrough spinal cord stimulation therapy across Europe, both for clinical and home use. The first commercial sales are expected in Q4 2025, starting in Germany before expanding…
Read MoreInkocell Therapeutics secures CHF 150,000 from Venture Kick
EPFL spin-off Inkocell Therapeutics, a Swiss biotech startup developing next-generation cell therapies, has secured CHF 150,000 from Venture Kick. The funding will accelerate the development of Inkocell’s first-in-class NK-tailored CAR (chimeric antigen receptor) technology, designed to create effective, safe, off-the-shelf, and affordable therapies for patients with life-threatening diseases. Over the past decade, engineered T-cell…
Read More